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Objectives This study sought to assess whether the volume of contrast media (CM) inﬂuences the
occurrence of acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI).
Background The volume of CM has been shown to be associated with increasing risk of AKI; how-
ever, in a high-risk elderly TAVI population, the predictive value and optimal threshold of CM dose
on AKI remain uncertain.
Methods Data of 415 consecutive transfemoral TAVI patients (age 83.6  6.8 years, logistic Euro-
SCORE 23.0  12.2%) were analyzed. AKI was deﬁned by Valve Academic Research Consortium crite-
ria. Based on a previous formula, the ratio of CM to serum creatinine (SCr) and body weight (BW)
(CM  SCr/BW) was calculated as deﬁning the degree of CM use. The association between CM dose
and incidence of AKI, as well as predictive factors and prognosis of AKI, were investigated.
Results AKI occurred in 63 patients (15.2%). Cumulative 1-year mortality showed signiﬁcant differ-
ences between the AKI and non-AKI groups (47.9% vs. 15.7%, p  0.001). Mean CM  SCr/BW ratio
was higher in the AKI group than in the non-AKI group (4.1  2.9 vs. 2.9  1.6, p  0.001). By mul-
tivariate analysis, CM  SCr/BW per 1.0 increase, ejection fraction 40%, and transfusion were asso-
ciated with the occurrence of AKI (odds ratio [OR]: 1.16; 95% conﬁdence interval [CI]: 1.03 to 1.20;
p  0.017, OR: 3.01; 95% CI: 1.49 to 5.00; p  0.001, OR: 2.73; 95% CI: 1.54 to 6.15; p  0.001, re-
spectively). A threshold value of CM  SCr/BW for predicting AKI was statistically identiﬁed as 2.7.
Conclusions Although mechanisms of AKI following TAVI are multifactorial, the present study identiﬁed
a relationship between CM dose increment and high prevalence of AKI. Therapeutic efforts not to ex-
ceed the threshold value may reduce the risk of AKI. (J Am Coll Cardiol Intv 2013;6:479–86) © 2013 by
the American College of Cardiology Foundation
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480First introduced in 2002, transcatheter aortic valve implan-
tation (TAVI) has emerged as a novel alternative procedure
enabling catheter-based treatment of high surgical risk
patients with symptomatic aortic stenosis) (1–5). Recent
reports have shown that acute kidney injury (AKI) occurs in
approximately 10% to 30% of patients undergoing TAVI
and is associated with early and late mortality (6–11). AKI
has been previously shown to increase midterm mortality in
patients undergoing cardiac surgery or interventional car-
diovascular procedures (12–16). The volume of contrast
media (CM) is considered a major factor of AKI and the
association between the occurrence of AKI and CM dosing
has long been the subject of study (17–22). Several previous
investigations have revealed that
CM  serum creatinine (SCr)
(in mg/dl)/body weight (BW)
(in kg) over 5.0 is associated
with an increased risk of kidney
injury or of the need for dialysis
after percutaneous coronary in-
tervention (19–22). Another ra-
tio, the total amount of CM
volume divided by the estimated
creatinine clearance (CCr), the
CM/CCr ratio, is also consid-
ered a useful tool (23,24). Al-
though efforts have been made
to identify predictors of AKI in
TAVI cohorts (6–11), there still
exists a paucity of data due to the
relatively small cohort size.
Moreover, it remains unclear
whether CM volume predicts
AKI in this high-risk TAVI co-
hort composed of very elderly
patients (6–11). The purpose of
the study reported here was
therefore to analyze the influ-
ence of renal function– based
contrast dosing on AKI.
Methods
Study population. The study population comprised 446
onsecutive patients with symptomatic aortic stenosis who
nderwent an elective transfemoral TAVI procedure in 2
rench centers (n  183, Henri Mondor University Hos-
ital from December 2007 to January 2012; and n  263,
acques Cartier Institution Hospital from October 2006 to
anuary 2012, respectively). Patients were selected for TAVI
hen considered unsuitable or high risk for surgical aortic
alve replacement by consensus between individual centers
nd heart team discussion. The operative risk was calculated
Abbreviations
and Acronyms
AKI  acute kidney injury
AR  aortic regurgitation
BW  body weight
CCr  creatinine clearance
CI  confidence interval
CM  contrast media
Cr  creatinine
eGFR  estimated
glomerular filtration rate
Euro SCORE  European
System for Cardiac Operative
Risk Evaluation
LVEF  left ventricular
ejection fraction
OR  odds ratio
RBC  red blood cell
ROC  receiver-operating
characteristic
SCr  serum creatinine
STS  Society of Thoracic
Surgeons Predictive Risk of
Mortality
TAVI  transcatheter aortic
valve implantationy using the logistic European System for Cardiac Opera-ive Risk Evaluation (Logistic EuroSCORE) and Society of
horacic Surgeons Predictive Risk of Mortality (STS)
core. High surgical risk was defined as Logistic
uroSCORE 20% or STS score 10% and also assessed
ccording to the presence of cardiac or noncardiac comor-
idities (25). Thirty-one patients were excluded because
hey were not eligible to undergo assessment of the inci-
ence of AKI: 12 patients were already receiving regular
emodialysis before TAVI, and 19 patients died within
2 h of TAVI. The analysis was performed in the 415
emaining patients. Clinical data, patient characteristics,
chocardiographic data, procedural variables, length of
ospital stay, and in-hospital and all-cause mortality rates
ere prospectively examined. Information about death
as obtained from the treating hospital or by phoning the
atient’s family. The medical ethics committees at both
ospitals approved this study protocol, and written in-
ormed consent was obtained from all patients before the
AVI procedure.
TAVI details and AKI analysis. TAVI procedures have al-
eady been described in detail (1–5,26–28). The Medtronic
oreValve Revalving System (Medtronic, Minneapolis,
innesota) or the Edwards Sapien valve (Edwards Life-
ciences, Irvine, California) were used. The femoral artery
as mainly approached percutaneously using a pre-closing
echnique (ProStar XL, Abbott Laboratories, North Chi-
ago, Illinois) (27). In the early phase of our experience, a
urgical approach was chosen in both centers (26,27). The
rosthesis size was determined from pre-procedural echo-
ardiographic and multislice computed tomographic find-
ngs (28). Rapid right ventricular pacing (range 160 to 200
eats/min) was performed during balloon dilation for native
ortic valves or implanted bioprosthetic valves. Iodixanol (320 mg
f iodine/ml; 290 mOsm/kg of water [Visipaque, GE Healthcare,
uc, France])—a nonionic, iso-osmolar, dimetric type of CM—
nd iohexol (Omnipaque, GE Healthcare) or iomeprol (Iomeron,
racco, Milano, Italy)—a nonionic, low-osmolar, monomet-
ic type of CM—were used. Catheterization or any other
invasive, significant) examinations requiring CM use were
voided for 72 h before TAVI. The estimated glomerular
ltration rate (eGFR) value was calculated using the Mod-
fication of Diet in Renal Disease equation: eGFR (ex-
ressed in ml/min/1.73 m2)  186  SCr1.154  age0.203
( 0.742 in the case of female patients) (29). The estimated
CCr was calculated using the Cockcroft-Gault method:
CCr (ml/min)  140  age (years)  BW (kg)/72  SCr
(mg/dl)  (0.85 in female patients) (29). Patients with
impaired renal function (eGFR 60 ml/min/1.73 m2)
received hydration and/or pre-treatment drugs (e.g.,
N-acetylcysteine) before TAVI, depending on the physi-
cian’s decision. The hydration regimens were adminis-
tered according to previous recommendations: isotonic
0.9% saline was started with an infusion rate of 1 ml/kg of
BW per h, 12 h before and continued 12 h after TAVI (30).
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481However, the hydration volume control varied in each
patient due to the presence of multiple comorbidities (a
wide age range, renal function, ejection fraction, pulmonary
artery pressure, and combined valvular disease).
According to the Valve Academic Research Consortium
criteria (31), AKI was defined as a change in SCr up to 72 h
compared with baseline, categorized as follows: stage 1, 1.5-
to 2-fold increase in SCr or an absolute increase in the
highest value of SCr (delta creatinine [Cr]) of 0.3 mg/dl
(26.4 mol/l); stage 2, 2.0- to 3.0-fold increase in SCr or
0.3 mg/dl (26.4 mol/l)  Cr 4.0 mg/dl (354
mol/l); stage 3, 3.0-fold increase in SCr or Cr 4.0
mg/dl (354 mol/l). Blood samples were obtained from
the antecubital vein 24 h before and after TAVI and once
daily for up to 72 h following TAVI. Other procedural
complications during TAVI were also assessed based on the
Valve Academic Research Consortium classification. The
CM  SCr/BW and CM/CCr ratios were used to evaluate
the degree of CM dose in individual patients according to
the previous investigations (19–24).
Statistics and data analysis. All statistical analyses were
erformed using SPSS software, version 19 (SPSS, Chicago,
llinois). Continuous variables were expressed as mean  SD
r median, depending on variable distribution. Categorical
ata were expressed as percentages of the total. The 2
roups were compared using the chi-square test or the
npaired Student t test, as appropriate. A univariate logistic
egression analysis was performed to obtain the odds ratio
OR) for AKI. Thereafter, a multivariate analysis was
erformed using the variables with p values 0.10 in the
nivariate analysis for examining their independent associ-
tion with AKI. Receiver-operating characteristic (ROC)
urve analyses were performed to examine the ability of the
M  SCr/BW and CM/CCr to identify the risk of AKI.
he threshold value–predicted AKI incidence in overall
atients was determined by the intersection of the sensitivity
nd specificity curves, if provided with statistically signifi-
ant differences. Kaplan-Meier methods were used to esti-
ate the cumulative survival rate in the AKI groups.
ifferences in survival in each group were compared with
he log-rank test. All statistical tests were 2-sided, and a
value 0.05 was considered significant.
esults
Baseline and procedural patient characteristics. AKI oc-
urred in 63 (15.2%) of the 415 study patients. Of these, 59
atients (93.7%) were categorized as AKI grade 2, and 4
ther patients (6.3%) requiring hemodialysis during the
ndex hospitalization were categorized as AKI grade 3.
aseline and procedural characteristics of patients according
o occurrence of AKI are shown in Table 1. The baseline
GFR (49.3  20.7 ml/min/1.73 m2 vs. 57.3  21.9ml/min/1.73 m2, p  0.008) and left ventricular ejection 0raction (LVEF) (45.2  14.5% vs. 50.4  14.5%, p 
.009) were significantly lower in the AKI group than in the
on-AKI. The degree of post-aortic regurgitation (AR) was
igher in the AKI group (1.23  0.82 vs. 1.01  0.77, p 
.041), and the prevalence of AR  grade 2 tended to be
igher in the AKI group (38.1% vs. 26.1%, p  0.051).
here was a trend toward higher prevalence of diabetes
30.2% vs. 20.5%, p  0.086) and mean pulmonary artery
ressure (53.1 15.1 mm Hg vs. 49.4 14.1 mm Hg, p
0.079) in the AKI group compared with the non-AKI
group. Procedural characteristics are shown in Table 2. The
total amount of CM, the CM  SCr/BW ratio, and
CM/CCr ratio were significantly higher in the AKI group
than in the non-AKI group (187.3  81.9 ml vs. 162.7 
76.9 ml; p  0.023, 4.1  2.9 vs. 2.9  1.6; p  0.001,
5.1  2.9 vs. 3.9  2.1; p  0.001, respectively). The type
of CM, iso-osmolar dimetric or low-osmolar monometric,
had no influence on the occurrence of AKI (p  0.47).
Divided into quartile serial series of this study population,
average CM dose showed a slight decrease across the 4 phases,
although not statistically significant (172.8 vs. 170.5 vs.
163.4 vs. 159.7 ml, p  0.59). The 30-day mortality rate
was 5.8% and was higher in AKI patients than in
non-AKI patients (15.9% vs. 4%, p  0.001). In addi-
tion, the rates of major vascular complications (15.9% vs.
8%, p  0.043) and red blood cell (RBC) transfusion
31.7% vs. 13.9%, p  0.044) were higher in the AKI
roup than in the non-AKI group.
Predictors of AKI. The logistic regression analysis of the
association between AKI and clinical findings is presented
in Table 3. Predictive factors for AKI were eGFR (per 1
ml/min/1.73 m2 increase), low LVEF (40%), CM 
Cr/BW (per 1.0 increase), post-AR (per 1 grade increase),
BC transfusion, and major vascular complication. In a
ultiple regression analysis (model 1), low LVEF, CM 
Cr/BW, and RBC transfusion were the only independent
redictive factors (OR: 2.73, 95% confidence interval [CI]:
.40 to 5.00: p  0.001; OR: 1.16, 95% CI: 1.03 to 1.20:
p  0.017; OR: 3.01, 95% CI: 1.54 to 6.15: p  0.001;
respectively). ROC analysis provided a modest discrimina-
tion with statistical significance in the CM  SCr/BW
values (area under the curve: 0.630, 95% CI: 0.55 to 0.71,
p  0.001) and the threshold value of CM  SCr/BW was
2.7 for predicting AKI (OR: 1.77, sensitivity: 60.7%,
specificity: 51.9%). Categories between CM  SCr/BW
2.7 and2.7 were compared for high-risk subgroups with
respect to the incidence of AKI (Fig. 1). Prevalence of AKI
with CM  SCr/BW 2.7 was also significantly higher
than that of AKI with CM  SCr/BW 2.7 in the
subgroups of eGFR 60 ml/min/1.73 m2 (26.1% vs.
11.9%, p  0.036), LVEF 40% (30.8% vs. 15.2%, p 
.033), and RBC transfusion (39.4% vs. 16.1%, p .033). The other multivariate model using CM/CCr
core.
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482(model 2) revealed that CM/CCr per 1.0 increase was
also identified as an independent predictor of AKI (OR:
1.24, 95% CI: 1.05 to 1.47; p  0.011) in addition to the
other 2 predictors. ROC analysis also provided a modest
discrimination in CM/CCr (area under the curve: 0.61, 95%
CI: 0.57 to 0.92; p  0.008) and a threshold value of
CM/CCr was 3.7 (OR: 1.77, sensitivity: 59.0%, specificity:
Table 1. Baseline Patient Characteristics
Overall
(N  415)
Baseline clinical characteristics
Age, yrs 83.6 6.8
Male 185 (44.6%)
Height, cm 162.8 8.8
BW, kg 68.7 14.1
Body mass index, kg/m2 25.9 4.7
Body surface area, m2 1.7 0.19
NYHA classiﬁcation III/IV 321 (77.3)
COPD 132 (31.8)
Peripheral artery disease 85 (20.5)
Prior myocardial infarction 54 (13.0)
Prior PCI 127 (30.6)
Prior stroke 38 (9.2)
Prior cardiac surgery 67 (16.1)
Diabetes mellitus 91 (21.9)
Hypertension 306 (73.7)
Dyslipidemia 201 (48.4)
Smoking 39 (9.4)
CCr, ml/min. 43.8 21.0
eGFR, ml/min./1.73 m2 56.1 21.8
eGFR 60 ml/min/1.73 m2 149 (35.9)
eGFR 45–60 ml/min/1.73 m2 130 (31.3)
eGFR 45 ml/min/1.73 m2 136 (32.8)
LVEF 40% 131 (31.6)
Logistic EuroSCORE, % 21.0 (14.4–28.9
STS score, % 7.4 (4.7–11.8)
Echocardiographic ﬁndings
LVEF, % 49.6 14.6
AVA, cm2 0.64 0.17
Mean aortic gradient, mm Hg 48.2 17.9
AR grade 0–4 0.85 0.73
MR grade 0–4 0.99 0.69
Pulmonary artery pressure, mm Hg 49.9 14.3
Post-procedural AVA, cm2 1.9 0.49
Post-mean aortic gradient, mm Hg 10.0 4.4
Post-AR grade 0–4 1.04 0.78
Post-AR grade 2 116 (28.0)
Post-MR grade 0–4 0.93 0.77
Values are mean SD, n (%), or median (interquartile range).
AKI acute kidney injury; AR aortic regurgitation; AVA aortic
obstructive pulmonary disease; eGFR estimated glomerular filtratio
LVEF left ventricular ejection fraction;MRmitral regurgitation; NY
STS score Society of Thoracic Surgeons Predictive Risk of Mortality s55.1%).Cumulative mortality and AKI. Clinical follow-up availabil-
ity was 100%, and median follow-up was 334 days (inter-
quartile range: 120 to 537 days). A total of 99 patients
(23.9%) died; of these, 31 patients were in the AKI group.
Kaplan-Meier analysis of cumulative mortality for the AKI
groups is presented in Figure 2. The cumulative 1-year
mortality was 45.7% in the AKI group and 15.7% in the
AKI
(n  63)
Non-AKI
(n  352) p Value
83.2 5.9 83.6 6.9 0.67
33 (52.4%) 152 (43.2%) 0.18
164.3 9.1 162.6 8.7 0.14
70.6 13.8 68.4 14.2 0.25
26.2 5.0 25.8 4.6 0.58
1.8 0.19 1.7 0.20 0.090
53 (84.1) 268 (76.1) 0.16
22 (34.9) 110 (31.3) 0.57
14 (22.2) 71 (20.2) 0.71
9 (14.3) 45 (12.8) 0.44
19 (30.2) 108 (30.7) 0.93
7 (11.1) 31 (8.8) 0.35
7 (11.1) 60 (17.0) 0.16
19 (30.2) 72 (20.5) 0.086
47 (74.6) 259 (73.6) 0.87
32 (50.8) 169 (48.0) 0.78
8 (12.7) 31 (8.8) 0.22
40.0 18.1 43.8 21.0 0.13
49.3 20.7 57.3 21.9 0.008
17 (27.0) 132 (37.5)
16 (25.4) 114 (32.4) 0.024
30 (47.6) 106 (30.1)
30 (47.6) 101 (28.7) 0.003
21.4 (15.9–29.4) 21.0 (14.4–28.6) 0.63
8.6 (5.0–14.5) 7.2 (4.7–11.0) 0.39
45.2 14.2 50.4 14.5 0.009
0.66 0.16 0.64 0.17 0.35
44.3 15.4 48.9 18.3 0.065
0.83 0.67 0.85 0.74 0.83
0.11 0.77 0.97 0.68 0.19
53.1 15.1 49.4 14.1 0.079
1.9 0.66 1.9 0.46 0.65
10.4 4.3 9.9 4.5 0.47
1.23 0.82 1.01 0.77 0.041
24 (38.1) 92 (26.1) 0.051
1.10 0.75 0.91 0.77 0.10
ea; BW body weight; CCr creatinine clearance; COPD chronic
uroSCORE European System for Cardiac Operative Risk Evaluation;
w York Heart Association; PCIpercutaneous coronary intervention;)
valve ar
n rate; E
HANenon-AKI group, respectively. The probability of cumulative
; other
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483mortality over the entire follow-up period after TAVI
significantly differed between the 2 groups (log-rank, p 
0.001).
Discussion
This study demonstrates that an increased CM  SCr/BW
ratio and CM/CCr may influence the incidence of AKI
Table 2. Procedural Patient Characteristics
Overall
(N  415
Peri-procedural variables
Procedure time, min 84.1 42
Fluoroscopy time, min 20.1 10
CM dose, ml 166.4 78.
Iso-osmolar dimetric CM 174 (41.9)
Low-osmolar monometric CM 241 (58.1)
CM  SCr/BW ratio 3.1 1.9
CM/CCr ratio 4.1 2.3
Medtronic CoreValve 212 (51.2)
Edwards Sapien 203 (48.9)
Post-procedural variables
Length of stay in hospital, day 8.0 7.7
Procedural success 396 (95.4)
30-day mortality 24 (5.8)
30-day combined safety endpoint 347 (83.6)
Myocardial infarction 2 (0.5)
Stroke 17 (4.1)
Major vascular complication 38 (9.2)
RBC transfusion 69 (16.6)
RBC transfusion 4 U 19 (4.6)
Two-valve implantation 9 (2.2)
New implantation of pacemaker 51 (12.3)
Cardiac tamponade 13 (3.1)
Surgery for vascular complication 15 (3.6)
Requirement of any cardiac surgery 6 (1.4)
Values are mean SD, n (%), or median.
CM contrast media; RBC red blood cell; SCr serum creatinine
Table 3. Multivariate Regression Analysis for the Predictive Factors of AKI
Univariate Analysis
OR 95% CI p Value
Diabetes 1.68 0.92–3.05 0.089
eGFR (per 1 ml/min/1.73 m2 increase) 0.98 0.97–0.99 0.008
LVEF 40% 2.26 1.31–3.90 0.003
Pulmonary artery pressure 1.02 0.99–1.04 0.080
CM  SCr/BW ratio (per 1.0 increase) 1.23 1.10–1.37 0.001
CM/CCr ratio (per 1.0 increase) 1.29 1.14–1.46 0.001
Post-AR (per 1 grade increase) 1.43 1.01–2.02 0.043
Red blood cell transfusion 2.88 1.56–5.30 0.001
Major vascular complication 2.18 1.00–4.75 0.049CI confidence interval; OR odds ratio; other abbreviations as in Tables 1 and 2.following TAVI in a relatively large TAVI cohort of 415
patients. Low LVEF (40%) and RBC transfusion were
also significant predictive factors of AKI. The cumulative
1-year mortality rate in the AKI group showed a 3-fold
increase compared with the non-AKI group (45.7% vs.
15.7%) and was consistent with previous reports (6–11).
The ratio of CM  SCr/BW 2.7 and CM/CCr 3.7 for
AKI
(n  63)
Non-AKI
(n  352) p Value
91.5 44.0 82.8 41.7 0.20
23.8 10.1 19.5 10.1 0.010
187.3 81.9 162.7 76.9 0.023
29 (16.6) 145 (41.2) 0.47
34 (14.1) 207 (58.8)
4.1 2.9 2.9 1.6 0.001
5.1 2.9 3.9 2.1 0.001
35 (55.6) 177 (50.3) 0.44
28 (44.4) 175 (49.7)
9.6 8.1 8.6 5.8 0.55
56 (88.9) 340 (96.6) 0.015
10 (15.9) 14 (4.0) 0.001
45 (71.4) 302 (85.8) 0.005
1 (1.6) 1 (0.3) 0.28
1 (1.6) 16 (4.5) 0.24
10 (15.9) 28 (8.0) 0.045
20 (31.7) 49 (13.9) 0.001
9 (14.3) 10 (2.8) 0.001
2 (3.2) 7 (2.0) 0.41
11 (17.5) 40 (11.4) 0.18
4 (6.3) 9 (2.6) 0.12
4 (6.3) 11 (3.1) 0.18
1 (1.6) 5 (1.4) 0.92
abbreviations as in Table 1.
Multivariate Analysis (Model 1) Multivariate Analysis (Model 2)
OR 95% CI p Value OR 95% CI p Value
2.73 1.49–5.00 0.001 2.73 1.40–5.32 0.003
1.16 1.03–1.20 0.017
1.24 1.05–1.47 0.011
3.01 1.54–6.15 0.001 3.01 1.41–6.49 0.005)
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484predicting AKI could be considered threshold values to
decrease the risk of AKI during TAVI. To the best of our
knowledge, this is the first study to demonstrate that a
simple formula integrating the amount of CM and renal
function may predict the risk of AKI after TAVI.
Figure 1. Patient Distribution of AKI
AKI incidence between CM  SCr/BW 2.7 and 2.7 for overall patients and
body weight; CM  contrast media; eGFR  estimated glomerular ﬁltration ra
Figure 2. Time-To-Event Curves for Cumulative Mortality
Mortality rate was calculated using Kaplan-Meier methods and compared
using the log-rank test according to the presence and absence of acuteo
kidney injury (AKI).Approximately 10% to 30% of patients undergoing TAVI
sustain kidney injury arising from various factors. AKI,
individually defined by elevations in SCr values, has been
associated with early or late adverse events, even when
kidney function damage was minimal (12–16). Although
CM use was not identified as an independent predictor of
AKI after TAVI in previous reports (6–11), it is still of the
utmost importance to know whether CM use should be
limited in TAVI procedures carried out in an elderly and
high-risk cohort. The present study demonstrates the rela-
tionship between AKI and CM dose calculated by CM 
Cr/BW and CM/CCr. Moreover, several factors may
nfluence the occurrence of AKI, and these were classified
nto patient clinical characteristics and procedural compli-
ations (32). The AKI-related risk of low LVEF, hemody-
amic instability, or hypotension with reduction in renal
lood supply became more apparent during conventional
atheter-based therapeutic procedures (17,18). A TAVI
rocedure carries an inherent risk of prolonged hypotension
nd hemodynamic changes due to rapid pacing during
alloon valvuloplasty and bioprosthetic valve implantation.
n addition, TAVI procedures in complex patients carry an
ncreased risk of RBC transfusion, vascular complications,
r other catastrophic complications compared with other
atheter-based therapeutic strategies, all of which may
otentially increase the risk of AKI. Several possible causes
patients of each subgroup are shown. AKI  acute kidney injury; BW 
F  left ventricular ejection fraction; SCr  serum creatinine.for thef AKI following TAVI should be taken into account. Our
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485data demonstrated that CM  SCr/BW was predictive of
KI, especially in the subgroups of low GFR, LVEF, and
atients requiring transfusion, supporting the multifactorial
athogenesis of AKI after TAVI.
The BW- and baseline SCr-adjusted maximum CM dose
CM  SCr/BW) was established as a criterion for preven-
tion of radiocontrast-induced nephropathy, and CM 
SCr/BW 5.0 was shown to be a predictor for the
occurrence of post-procedural kidney injury (19–22). The
assessment of the CCr-adjusted maximum CM dose, CM/
CCr, was also useful for risk stratification of post-procedural
nephropathy and has been recommended to be kept under
3.7 or not to exceed 3.0 (23,24). After stratification for the
CM  SCr/BW and CM/CCr factors, our data indicated
that the threshold values using the ROC curve to predict
AKI were 2.7 and 3.7, respectively. Although the cutoff
value of CM/CCr was thought to be similar, CM 
SCr/BW was lower in comparison with the previous thresh-
old. This discrepancy may be explained by significant
differences in the individual background of patients com-
posing this very elderly TAVI population. In the current
study, mean estimated eGFR and CCr values were 56.1 and
43.8 ml/min, respectively. The average CM dose was 166.4
78.1 ml. By contrast, previous studies revealed that more
than 70% of patients maintained the eGFR value or CCr
60 ml/min, with an average CM dose over 200 ml
(20–24). This result means that similar CM value thresh-
olds may be interpreted differently. Absolute CM dose
should be more restricted in the TAVI cohort to stay under
the previous recommended cutoff value. A reported study
using transesophageal echocardiography revealed a signifi-
cant volume reduction of CM during TAVI (33). We also
show in the present study a slight reduction in average CM
use (about 10 to 15 ml) in serial quartile study periods.
Several possible approaches and device improvements may
reduce the CM volume. It is noteworthy that CM overdos-
ing may be a more powerful predictor of AKI when
combined with other predictive factors of AKI, such as
impaired renal function (eGFR 60 ml/min/1.73 m2),
VEF 40%, and RBC transfusion. Classifying TAVI
atients into high-risk categories and making all possible
fforts to reduce the amount of CM used during TAVI
rocedures could prove clinically important. The outcome is
idely known to be worse in patients with AKI. Our results
emonstrated a finding that was in line with previous
linical studies (6–16). In order to improve prognosis, risk
tratification is required to reduce the risk of subsequent
KI. Further investigations are warranted to establish
hether use of limited CM doses may prevent or minimize
KI following TAVI.
Study limitations. Our study reports a prospective TAVI
cohort from 2 centers in France that is not large enough
to establish the definite cutoff point for CM dose. We
opted to include recipients of both the Edwards valve andthe CoreValve, as this mixed cohort reflected our real
clinical experience. Although the CM dose was identified
as one of the independent predictors of AKI, the inci-
dence of AKI during TAVI can be multifactorial. Esti-
mation of the renal function by using the Modification of
Diet in Renal Disease equation or Cockcroft-Gault
method in elderly patients is limited in terms of reliability
(34). On the basis of the aforementioned limitations, the
current limits of both CM  SCr/BW and CM/CCr
ratios should not be considered a definitive threshold. In
addition, the serial change in renal function is clinically
important, especially in this group of patients with AKI
after TAVI. Other factors confounding the association
with AKI may have been neglected in this study. Al-
though hemodynamic instability during the procedure is
a well-known predictive factor for AKI (17,18), the
precise degree of hemodynamic instability during TAVI
is difficult to assess. Among the nineteen patients who
died within 72 h of the procedure, the vast majority of
them with cardiogenic shock, were excluded from the
initial analysis.
Conclusions
Increasing CM dose as assessed by CM  SCr/BW or
CM/CCr is associated with the occurrence of AKI follow-
ing TAVI. The occurrence of AKI has become a strong
factor of increased late mortality after TAVI. Therapeutic
efforts to reduce the CM dose should be strongly encour-
aged for TAVI procedures.
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